Oppenheimer Keeps Their Buy Rating on Mediwound (MDWD)

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Mediwound (MDWD) yesterday and set a price target of $7.00. The company’s shares closed last Wednesday at $4.84.

According to TipRanks.com, DeGeeter is a top 100 analyst with an average return of 57.6% and a 62.2% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mediwound with a $6.17 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $4.44 and a one-year low of $1.44. Currently, Mediwound has an average volume of 77K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MediWound Ltd. is a biopharmaceutical company engaging in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product is NexoBrid. The company was founded by Lior Rosenberg and Marian Gorecki in 2001 and is headquartered in Yavne, Israel.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts